000130448 001__ 130448
000130448 005__ 20240125162930.0
000130448 0247_ $$2doi$$a10.1177/1753425909104781
000130448 0248_ $$2sideral$$a116144
000130448 037__ $$aART-2009-116144
000130448 041__ $$aeng
000130448 100__ $$aMendoza, Carmen
000130448 245__ $$aLipopolysaccharide induces alteration of serotonin transporter in human intestinal epithelial cells
000130448 260__ $$c2009
000130448 5203_ $$aIntestinal serotoninergic activity and serotonin transporter (SERT) function have been shown to be altered in intestinal inflammatory diseases. Serotonin (5-HT) plays a critical role in the regulation of gastrointestinal physiology. Activity of 5-HT depends on its extracellular availability, partly modulated by SERT that transports 5-HT into the cell. Lipopolysaccharide (LPS) is a component of Gram-negative bacteria outer membrane, which acts as a potent activator of the inflammatory system in the intestine. The aim of this work was to determine, in the enterocyte-like cell line Caco-2, whether LPS treatment affects serotoninergic activity by acting on SERT. The results demonstrate that LPS treatment diminishes SERT activity in a dose- and period-dependent way. The kinetic study shows that V<inf>max</inf> was significantly reduced after treatment with LPS. The LPS effect on 5-HT uptake was, in part, mediated by protein kinase C (PKC) activation. The molecular expression of SERT revealed that LPS treatment did not affect the mRNA level or the SERT protein content in cell homogenate. The level of SERT protein, however, was reduced on brush border membrane. The LPS effect might be due to an alteration of the intracellular traffic of SERT which may, in part, be mediated by PKC activity. © SAGE Publications 2009.
000130448 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000130448 590__ $$a2.206$$b2009
000130448 591__ $$aMEDICINE, RESEARCH & EXPERIMENTAL$$b41 / 91 = 0.451$$c2009$$dQ2$$eT2
000130448 591__ $$aMICROBIOLOGY$$b54 / 95 = 0.568$$c2009$$dQ3$$eT2
000130448 591__ $$aBIOCHEMISTRY & MOLECULAR BIOLOGY$$b177 / 281 = 0.63$$c2009$$dQ3$$eT2
000130448 591__ $$aIMMUNOLOGY$$b87 / 126 = 0.69$$c2009$$dQ3$$eT3
000130448 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000130448 700__ $$0(orcid)0000-0002-1605-0542$$aMatheus, Nyurky
000130448 700__ $$aIceta, Ruth$$uUniversidad de Zaragoza
000130448 700__ $$0(orcid)0000-0003-4758-3998$$aMesonero, Jose E.$$uUniversidad de Zaragoza
000130448 700__ $$0(orcid)0000-0002-9935-927X$$aAlcalde, Ana I.$$uUniversidad de Zaragoza
000130448 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000130448 773__ $$g15, 4 (2009), 243-250$$pInnate immun.$$tInnate Immunity$$x1753-4259
000130448 8564_ $$s198077$$uhttps://zaguan.unizar.es/record/130448/files/texto_completo.pdf$$yVersión publicada
000130448 8564_ $$s902508$$uhttps://zaguan.unizar.es/record/130448/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000130448 909CO $$ooai:zaguan.unizar.es:130448$$particulos$$pdriver
000130448 951__ $$a2024-01-25-15:11:30
000130448 980__ $$aARTICLE